Dual-isocenter MR-Linac workflow treats 24-cm prostate and pelvic targets in one patient

A dual-isocenter MR-Linac workflow treated a 24-cm continuous prostate and pelvic target, achieving high gamma passing rates in its first clinical application.

KEY POINTS

  • This technical report describes the first clinical application of a dual-isocenter field-junction technique for long continuous targets on a 1.5-T MR-Linac. The patient was a 79-year-old man with cT2cN1M1b prostate cancer, including a left pubic bone metastasis, enrolled in the SMART-P02 prospective phase II study. The combined prostate and pelvic treatment volumes extended approximately 24 cm craniocaudally, exceeding the 22-cm maximum treatment field length of the Elekta Unity MR-Linac.
  • Six target structures received differentiated prescriptions over five alternate-day fractions. Prescriptions included 36.25 Gy to the prostate PTV, 40 Gy to CTV4000, 25 Gy to the pubic bone PTV, 35 Gy to the gross pubic metastasis, 25 Gy to the pelvic nodal PTV, and 35 Gy to gross nodal disease. Alternative lower prescriptions of 23.5 Gy for the pelvic nodal PTV and 30 Gy for gross nodal disease were permitted when initial coverage objectives conflicted with organ-at-risk constraints.
  • The technique divided the continuous treatment volume into two overlapping regions with independent isocenters. Inferior and superior composite volumes were each approximately 12 cm long, with isocenters separated by 7 cm and a 2.4-cm overlap region. The inferior volume underwent online adapt-to-shape optimization, while the superior plan incorporated offline dose feathering based on the inferior dose distribution, followed by online adapt-to-position optimization. Composite dose summation was performed to assess junction homogeneity and organ-at-risk exposure.
  • Patient-specific quality assurance demonstrated favorable dosimetric agreement. ArcCHECK gamma passing rates using 3%/2 mm criteria with a 10% threshold were 96.7% for the inferior reference plan, 97.1% for the superior reference plan, and 96.0% for the composite plan. Across five adaptive fractions, independent ArcherQA verification produced passing rates of 97.08–98.43% for inferior plans and 98.12–98.74% for superior plans. No clinically significant junction hot or cold spots were identified on the reported dose assessments.
  • Primary prostate and pubic bone targets achieved high coverage, while pelvic nodal coverage required compromises. Mean adaptive CTV4000 V40Gy was 96.82%, prostate PTV V36.25Gy was 96.16%, pubic metastasis PGTV V35Gy was 98.76%, and pubic PTV V25Gy was 99.94%. By contrast, gross nodal PGTV V35Gy averaged 75.39%, while pelvic nodal PTV V25Gy averaged 89.76%. These reductions reflected bowel proximity and the use of lower alternative target prescriptions rather than consistently meeting the original dose objectives.
  • Normal-tissue protection was prioritized when target coverage conflicted with bowel exposure. Rectal and bladder parameters remained within the stated planning limits. However, bowel-bag V25Gy exceeded 100 cm³ in fractions one and two, reaching 141.8 and 152.5 cm³, before decreasing to approximately 53–65 cm³ in subsequent fractions. The study illustrates a technical trade-off between extensive target coverage and gastrointestinal protection, rather than uniformly achieving all original target and OAR planning objectives.
  • Treatment times improved over five fractions, but the workflow remained resource-intensive. Total treatment time decreased from 112 minutes in fraction one to 80 minutes in fraction five, primarily through shorter contouring, review, and adaptive planning steps rather than beam delivery. During approximately three months of follow-up, no patient-reported genitourinary or gastrointestinal toxicity was documented. FACT-P quality-of-life score decreased from 69.17 at baseline to 55.5 at treatment completion, partially recovering to 57.5 at 2.5 months. With only one treated patient, clinical safety, reproducibility, and long-term effectiveness remain unestablished.

CLINICAL TAKEAWAY

A dual-isocenter adaptive workflow enabled treatment of a continuous 24-cm prostate and pelvic target exceeding the standard field-length limit of a 1.5-T MR-Linac. Initial dosimetric verification was favorable, although pelvic nodal coverage required compromise and treatment sessions lasted 80–112 minutes. This single-patient technical experience supports further feasibility testing but cannot establish routine clinical safety, efficiency, or oncological effectiveness.

SOURCE

Journal of Applied Clinical Medical Physics

Browse more research Suggest a correction